Document is current
Any future updates will be listed below
-
Authors
Dikiy, Stanislav https://orcid.org/0000-0002-8287-6561
Ghelani, Aazam P.
Levine, Andrew G.
Martis, Stephen https://orcid.org/0000-0003-1735-2347
Giovanelli, Paolo https://orcid.org/0000-0002-5799-6721
Wang, Zhong-Min https://orcid.org/0000-0002-5538-1969
Beroshvili, Giorgi
Pritykin, Yuri https://orcid.org/0000-0001-6589-981X
Krishna, Chirag
Huang, Xiao
Glasner, Ariella
Greenbaum, Benjamin D. https://orcid.org/0000-0001-6153-8793
Leslie, Christina S. https://orcid.org/0000-0002-4571-5910
Rudensky, Alexander Y. https://orcid.org/0000-0003-1280-2898
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01 AI034206)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
Howard Hughes Medical Institute (HHMI0)
Ludwig Institute for Cancer Research (Ludwig0)
- License Information
-
More Information
Article History
Received: 27 June 2022
Accepted: 30 December 2024
First Online: 4 February 2025
Competing interests
: A.Y.R. is a scientific advisory board member and has equity in Sonoma Biotherapeutics, RAPT Therapeutics, Coherus, Odyssey Therapeutics, Nilo Therapeutics, Santa Ana Bio and Vedanta Biosciences, and is a scientific advisory board member of BioInvent and Amgen and a co-inventor or has intellectual property licensed to Takeda that is unrelated to the content of the present study. The other authors declare no competing interests.
